Evidence map›Paper›PMID 27284341›Full record

ArticleExperimental and therapeutic medicine2016

MicroRNA-138 suppresses proliferation, invasion and glycolysis in malignant melanoma cells by targeting HIF-1α.

Yao Chen, K E Cao, Shaohua Wang, Jia Chen, Bin He, G U He, Yong Chen, Bin Peng, Jianda Zhou

RetractedOpen access · diamondAbstract readRetracted Publication
In one paragraph

Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Hypoxia-dependent drivers of melanoma progression.Journal of experimental & clinical cancer research : CR · 2021
    Review
  9. Article
  10. Article
  11. Review
  12. The miRNAs Role in Melanoma and in Its Resistance to Therapy.International journal of molecular sciences · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yao ChenDepartment of Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China; Department of Plastic Surgery, Longgang Orthopedics Hospital of Shenzhen, Shenzhen, Guangdong 518116, P.R. China.
K E CaoDepartment of Oncology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
Shaohua WangDepartment of Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
Jia ChenDepartment of Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
Bin HeDepartment of Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
G U HeDepartment of Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
Yong ChenDepartment of Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
Bin PengDepartment of Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
Jianda ZhouDepartment of Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
Third Xiangya Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRs) may induce mRNA degradation or inhibit protein translation by directly binding to the 3'-untranslational region of target mRNAs. It has been reported that miR-138 is downregulated in malignant melanoma (MM) cells. However, the role of miR-138 in MM cell proliferation, invasion and energy metabolism remains unknown. These were investigated using reverse transcription-quantitative polymerase chain reaction was used to evaluate the expression of miR-138 and the mRNA expression of hypoxia-inducible factor-1α (HIF-1α), as HIF-1α serves a crucial role in glycolysis, which is important for tumor growth. In addition, western blot analysis was used to detected the protein expression of HIF-1α, while MTT and Transwell assays evaluated cell proliferation and invasion, respectively. Furthermore, glucose consumption and lactic acid production were assessed. These tests were conducted using the normal human melanocyte cell line HM and the MM cell line WM451, which was transfected variously with scramble miR mimics, miR-138 mimics, miR-138 inhibitor, non-specific small interfering (si)RNA, HIF-1α siRNA, or co-transfected with miR-138 mimics and pc-DNA3.1(+)-HIF-1α plasmid. The results showed that miR-138 was significantly downregulated in MM WM451 cells compared to a normal melanocyte cell line HM. Overexpression of miR-138 significantly inhibited the proliferation and invasion of WM451 cells. These effects were similar to those induced by the siRNA-mediated knockdown of HIF-1α, a direct target of miR-138. Further investigation found that miR-138 negatively regulated the protein expression of HIF-1α in WM451 cells. Moreover, upregulation of miR-138 notably inhibited the glycolysis level, as demonstrated by reduced glucose consumption and lactic acid production, which could be reversed by the overexpression of HIF-1α. In summary, the present study demonstrated that miR-138 is able to inhibit proliferation, invasion and glycolysis in MM cells, potentially by directly targeting HIF-1α.

Indexed as

glycolysishypoxia-inducible factor-1αinvasionmelanomamicroRNA-138proliferation

Identifiers

PMID27284341
PMCPMC4887928
OpenAlexW2337344543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.